Login   |  Users Online: 1006 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size
Search Article 
  
Advanced search 
   Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts
CLINICAL RESEARCH
Year : 2010  |  Volume : 31  |  Issue : 2  |  Page : 197-204

A short-term intervention trial on HIV positive patients using a Sri Lankan classical rasayana drug - Ranahamsa Rasayanaya


1 Department of Kayachikitsa, Institute for Post Graduate Teaching and Research in Ayurveda, Gujarat Ayurved University, Jamnagar, Gujarat, India
2 Department of Pharmacology Laboratory, I.P.G.T.& R.A., Jamnagar,Gujarat,India
3 Department of Medicine, Infectious Disease Ward, M.P. Shah Medical College, Jamnagar,Gujarat,India
4 Department of Medicine, M.P.I.Y.N.E.R., Gujarat Ayurved University, Jamnagar, Gujarat, India

Correspondence Address:
K.I.W.K Somarathna
Lecturer, Department of Kayachikitsa, Institute of Indigenous Medicine, University of Colombo, Rajgiriya, Sri Lanka

Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0974-8520.72393

Rights and Permissions

Rational use of Rasayana therapy, in the management of HIV infected individuals, could potentially stabilize the destructive control mechanisms, by modulating the psycho-neuro-endocrine-immune axis. The objective of the present study has been to determine the short-term effects of Ranahamsa Rasayanaya (RR) in HIV infected patients. A total of 27 patients with documented HIV infection were randomly assigned to two groups, Group A - 5 g of RR twice daily with cow's milk and sugar. Group B - Only routine modern therapy was continued, if any they were taking, including highly active anti-retroviral therapy (HAART). Absolute CD4 + T-cell and total lymphocyte counts were measured in these patients, registered under Group A. Only 21 participants completed the study protocol (In Group A, 15 patients and in Group B, 6 patients). Initial mean CD4 + T-cell count was 304.50 ± 43.36 cells/microliter, which increased to 430.44 ± 66.01 cells/microliter by 41.36% (P<0.05), measured among 9 patients out of 15, who received RR in Group A. The RR seemed to be a safer adjuvant in people with HIV infection with respect to absolute CD4 + T-cell count over a 90 days treatment.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed4412    
    Printed137    
    Emailed0    
    PDF Downloaded438    
    Comments [Add]    
    Cited by others 1    

Recommend this journal